Vanda Pharmaceuticals | VNDA - Selling And Administration Expenses


Vanda Pharmaceuticals reported $39.28M in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
Agios Pharmaceuticals USD 51.55M 13.09M Jun/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.63M 4.88M Jun/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Halozyme Therapeutics USD 58.24M 1.24M Sep/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 253.03M 5.56M Sep/2026
J&J USD 6.25B 168M Sep/2026
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Ligand Pharmaceuticals USD 72.62M 43.49M Sep/2026
Merck USD 2.86B 25M Sep/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 216M 43M Jun/2026
Novartis USD 3.08B 58M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
PTC Therapeutics USD 80.63M 6.74M Jun/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.31B 325M Sep/2026
Takeda JPY 271.71B 14.8B Sep/2026
Teva Pharmaceutical Industries USD 1.01B 27M Sep/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Veracyte USD 57.95M 2.25M Sep/2026